Janux Therapeutics has commenced Phase Ib expansion trials with JANX007 in the first-in-human ENGAGER-PSMA-01 clinical trial.

Research and development (R&D) investment in the Swiss biotech sector grew in 2024, despite ongoing global funding struggles.

Chengdu Origen and Vanotech have initiated the first subject dosing in the Phase I trial, VAN-2401, of KH658 for treating wet ...

OBI Pharma has received clearance from the US FDA for an IND application for OBI-902 to begin a Phase I/II trial for advanced ...

Europe meeting, experts discussed the challenges and strategies of small and mid-sized biopharma companies surrounding ...

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

AstraZeneca plans to submit the positive data Breztri Aerosphere in asthma for to regulatory authorities for review.

Amylyx has dosed the first subject in the Phase III LUCIDITY trial of avexitide for treating post-bariatric hypoglycaemia ...

The upcoming 12th Annual Clinical Trials in Oncology conference will cover a wide range of topics on clinical research in ...

BioCardia has announced the enrolment of the first subject in CardiAMP HF II trial of its cell therapy for treating heart ...

Tempus AI has announced that it is using the TIME Network for Phase I trials to expedite site activation and enrolment.

Neurocrine has commenced a Phase III registrational programme to assess NBI-1117568 as a treatment for schizophrenia in adult ...